Get the Stockscreener App
41.96
6.61%
2.60
Ptc Therapeutics Inc stock is traded at $41.96, with a volume of 701.41K.
It is up +6.61% in the last 24 hours and up +7.31% over the past month.
See More
Previous Close:
$39.36
Open:
$39.38
24h Volume:
701.41K
Relative Volume:
1.04
Market Cap:
$3.30B
Revenue:
$900.45M
Net Income/Loss:
$-479.52M
P/E Ratio:
-4.8509
EPS:
-8.65
Net Cash Flow:
$-230.14M
1W Performance:
-4.70%
1M Performance:
+7.31%
6M Performance:
+4.59%
1Y Performance:
+89.26%
1-Day Range:
$38.26
$42.79
1-Week Range:
$38.26
$44.28
52-Week Range:
$20.75
$46.98
Ptc Therapeutics Inc Stock (PTCT) Company Profile
Name
Ptc Therapeutics Inc
Sector
Industry
Phone
(908) 222-7000
Address
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Compare PTCT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| PTCT | 41.96 | 3.30B | 900.45M | -479.52M | -230.14M | -8.65 |
| VRTX | 451.23 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 743.35 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.82 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.79 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.14 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Oct-30-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-27-23 | Downgrade | Citigroup | Neutral → Sell |
| Oct-06-23 | Downgrade | Truist | Buy → Hold |
| Sep-18-23 | Downgrade | Citigroup | Buy → Neutral |
| Sep-15-23 | Downgrade | Raymond James | Outperform → Underperform |
| Mar-17-23 | Initiated | SVB Securities | Market Perform |
| Dec-14-22 | Initiated | Goldman | Sell |
| Sep-12-22 | Initiated | Jefferies | Buy |
| Sep-09-22 | Initiated | Morgan Stanley | Equal-Weight |
| Sep-01-22 | Initiated | Citigroup | Buy |
| Apr-04-22 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-18-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Apr-26-21 | Resumed | Credit Suisse | Neutral |
| Mar-29-21 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Feb-12-21 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-05-21 | Upgrade | Citigroup | Neutral → Buy |
| Nov-30-20 | Downgrade | RBC Capital Mkts | Sector Perform → Underperform |
| Oct-30-20 | Downgrade | Citigroup | Buy → Neutral |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-07-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Apr-09-20 | Upgrade | Citigroup | Neutral → Buy |
| Feb-20-20 | Downgrade | Citigroup | Buy → Neutral |
| Feb-20-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-12-19 | Initiated | SunTrust | Buy |
| May-13-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Apr-11-19 | Initiated | Bernstein | Outperform |
| Oct-03-18 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-19-18 | Initiated | Credit Suisse | Outperform |
| Jun-18-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Apr-04-18 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-29-18 | Resumed | RBC Capital Mkts | Sector Perform |
| Nov-16-17 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-26-17 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Oct-09-17 | Downgrade | JP Morgan | Neutral → Underweight |
View All
Ptc Therapeutics Inc Stock (PTCT) Latest News
Phenylketonuria Market size is ~700 USD million in 2023, asserts DelveInsight | Pharma Giants: PTC Therapeutics, Homology Medicines, Synlogic, BioMarin Pharmaceuticals - The Globe and Mail
PTC Therapeutics (PTCT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates - MSN
PTC Therapeutics (NASDAQ:PTCT) Price Target Raised to $62.00 - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Rating Lowered to Hold at StockNews.com - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Shares Down 7.4%Time to Sell? - MarketBeat
ARMISTICE CAPITAL, LLC Acquires Additional Shares in PTC Therape - GuruFocus.com
PTC Therapeutics wins FDA nod for gene therapy - MSN
PTC Gets US FDA Approval For Brain-Delivered Gene Therapy - Citeline News & Insights
PTC Therapeutics Wins First FDA Approval for a Gene Therapy Dosed Directly Into the Brain - MedCity News
FDA Grants Conditional Approval For PTC Therapeutics' Gene Therapy As First Ever With Direct Administration In Brain - AOL
AADC deficiency gene therapy, called Kebilidi, now approved in US - AADC News
FDA Approves Eladocagene Exuparvovec-Tneq for Treatment of AADC Deficiency - Pharmacy Times
PTC wins US approval of gene therapy for fatal enzyme disorder - BioPharma Dive
PRV sweetens PTC approval of Kebilidi in AADC deficiency - BioWorld Online
FDA grants accelerated approval for PTC’s AADC deficiency gene therapy - Yahoo Finance
FDA nod for AADC deficiency gene therapy from PTC - The Pharma Letter
PTC Therapeutics' Gene Therapy For AADC Deficiency Approved By FDA - Contract Pharma
PTC Therapeutics wins FDA nod for gene therapy (PTCT:NASDAQ) - Seeking Alpha
PTC Wins First FDA Nod for Direct-to-Brain Gene Therapy, Targets Ultrarare Disease - BioSpace
PTC gets FDA okay for first brain-delivered gene therapy - pharmaphorum
US FDA approves PTC Therapeutics' gene therapy for ultra-rare disorder - Reuters.com
PTC Therapeutics Wins FDA Approval for Groundbreaking Brain Gene Therapy KEBILIDI | PTCT Stock News - StockTitan
PTC Therapeutics's SWOT analysis: rare disease biotech stock faces pivotal year - Investing.com India
Barclays Issues Positive Forecast for PTC Therapeutics (NASDAQ:PTCT) Stock Price - MarketBeat
PTC Therapeutics, Inc. (NASDAQ:PTCT) Q3 2024 Earnings Call Transcript - Insider Monkey
PTC Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St
PTC Therapeutics, Inc. (NASDAQ:PTCT) Receives $40.38 Average Target Price from Analysts - MarketBeat
PTC Therapeutics Inc (PTCT) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
Earnings call: PTC Therapeutics raises 2024 revenue outlook - Investing.com
Wellington Management Group LLP's Strategic Reduction in PTC The - GuruFocus.com
PTC data hot as Larimar, others advance in Friedreich’s ataxia - BioWorld Online
PTC Therapeutics Inc (PTCT) Q3 2024 Earnings Call Highlights: Re - GuruFocus.com
PTC Therapeutics (NASDAQ:PTCT) Shares Gap Up Following Analyst Upgrade - MarketBeat
PTC Therapeutics Inc (PTCT) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ... - Yahoo Finance
PTC Therapeutics (NASDAQ:PTCT) Price Target Raised to $48.00 - MarketBeat
PTC Therapeutics (PTCT) Reports Q3 Loss, Tops Revenue Estimates - MSN
PTC Therapeutics: Q3 Earnings Snapshot - Houston Chronicle
PTC Therapeutics Reports Strong Q3 2024 Performance - TipRanks
PTC Therapeutics Inc (PTCT) Q3 2024 Earnings: Revenue Surges to $196.8M, Beating Estimates; GAAP EPS at -$1.39 - GuruFocus.com
PTC Therapeutics earnings beat by $0.12, revenue topped estimates - Investing.com UK
PTC Therapeutics Raises 2024 Guidance as Q3 Revenue Hits $196.8M, Pipeline Expands | PTCT Stock News - StockTitan
PTC Therapeutics (NASDAQ:PTCT) Hits New 52-Week HighWhat's Next? - MarketBeat
Unlocking Q3 Potential of PTC Therapeutics (PTCT): Exploring Wall Street Estimates for Key Metrics - MSN
Duchenne Muscular Dystrophy (DMD) Therapeutics Market to Grow by USD 4.37 Billion from 2024-2028, Driven by High Unmet Needs and AI-Powered Market EvolutionTechnavio - The Malaysian Reserve
PTC Therapeutics Inc (PTCT) Q3 2024: Everything You Need To Know Ahead Of Earnings - GuruFocus.com
PTC Therapeutics to Participate at Upcoming Investor Conferences - StockTitan
PTC Therapeutics resubmitted NDA for Translarna accepted by FDA - MSN
PTC Therapeutics (PTCT) Scheduled to Post Earnings on Thursday - MarketBeat
FDA Accepts Resubmission of Translarna NDA for Duchenne - Managed Healthcare Executive
PTC Therapeutics (NASDAQ:PTCT) Hits New 12-Month HighHere's What Happened - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) grows 8.1% this week, taking one-year gains to 127% - Yahoo Finance
Ptc Therapeutics Inc Stock (PTCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.69%
6.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):